CA-XSOLLA/GDC
21.3.2022 12:02:11 CET | Business Wire | Press release
Xsolla , a global video game commerce company, is attending and presenting at GDC (Game Developers Conference) , the biggest game conference in the world, today through March 25th in San Francisco, California, USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005435/en/
Xsolla is hosting six informative speaking sessions on Tuesday, March 22nd, including a keynote from President Chris Hewish. Additionally, Xsolla is exhibiting at Moscone South S657, starting on Wednesday, March 23rd, where attendees can meet with Xsolla experts and get a preview of the latest products and solutions designed to accelerate video game commerce in 2022.
“I’m excited to return to GDC in person and to kick off Xsolla’s series of trending topic speaker sessions,” Hewish said. “It’s great to see old friends and meet new people from all over the world who share our passion for video games.”
The Xsolla team is sharing industry updates and their expertise on the tools and services available for video game developers and publishers. Topics will range from mobile game monetization outside of the app store, payments for the enterprise , and token-based systems for digital content with a new NFT Checkout to emerging market opportunities and prelaunch funding . Video-on-demand of the sessions will be available later in the week for those who could not attend to watch and learn.
Tuesday, March 22 | 9:30am - 10:30am [Add to iCal
]
GOING GLOBAL, STAYING LOCAL: HELPING GAME DEVELOPERS SUCCEED
Great games don’t just appear. They start as ideas, and only through the curiosity, dedication, and grit of people all over the globe do they come to life. Xsolla President Chris Hewish outlines ways to ensure that every developer has the same opportunity to see their game become a part of how we play.
Tuesday, March 22 | 10:50am - 11:50am [Add to iCal
]
INSIDE THE WALLED PAYMENT GARDEN: A GUIDE TO MOBILE MARKET FREEDOM
In this session, Anthony Mendoza and Miikka Luotio share a frank discussion on how developers can break into mobile gaming's 'walled payment garden' and grow their games just as many others have already done.
Tuesday, March 22 | 1:20pm - 1:50pm [Add to iCal
]
GAME OF FUNDS: SUCCESS IS COMING
Xsolla’s dynamic duo of funding, Justin Berenbaum and Lily Goldner, host special guests David Martinez from Raw Fury and Ken Seto from Massive Damage Games in a fireside chat, where you’ll discover how to improve your chances and create business alliances.
Tuesday, March 22 | 2:10pm - 2:40pm [Add to iCal
]
BEYOND CREDIT: TAKING ADVANTAGE OF EMERGING PAYMENT METHODS
WORLDWIDE
"Cash, check or charge?" It used to be that these were the only options when handling payments. Now there are hundreds. Berkley Egenes leads a team of Xsolla regional experts as they discuss how to control the chaos and take advantage of emerging payment methods around the globe.
Tuesday, March 22 | 3:00pm - 3:30pm [Add to iCal
]
"THINGS I WISH I KNEW SOONER" ABOUT THE GAME INDUSTRY
Xsolla's Sam Gaglani hosts a panel of games industry pros, including Kara Bilkiss from Rogue Games, Michael Lewis from Take-Two Interactive, and Andreea Enache from Secret Society Games who've "been there, done that" as they share their wisdom and insights. They will focus on topics that affect developers at any studio and discuss things they wish they had known sooner about working in the industry.
Tuesday, March 22 | 3:50pm - 4:20pm [Add to iCal
]
HYBRID TIMES: GAME DEVELOPERS SOUND OFF ON WORKING FROM HOME, COMPENSATION, AND CAREER
The industry-leading platform 80 Level asked the gaming community about recent challenges and opportunities, and over 800 game developers shared their experiences. Kirill Tokarev, Editor in Chief at 80 Level, highlights what these responses reveal about our past and what the future has in store.
Book a meeting with Xsolla’s global game commerce experts to discover how they can help expand your video game commerce in the changing games industry.
For more information on how to attend speaking sessions and connect with Xsolla at GDC 2022, visit https://xsolla.com/gdc2022
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes to promote and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world to support major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more. For additional information and to learn more, please visit xsolla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005435/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom